Verve Therapeutics is a biotechnology company focused on developing novel gene editing therapies to address cardiovascular disease. Their lead candidate, VERVE-102, is an experimental gene-editing therapy designed to permanently lower LDL cholesterol (bad cholesterol) after a single infusion. The therapy works by targeting PCSK9, a gene that plays a key role in regulating cholesterol levels. Early clinical trial results have shown promising safety and efficacy, with significant reductions in LDL cholesterol observed.